Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1

A 38-year-old woman with MS receiving natalizumab presented to the neurology clinic with the complaint of a new neurologic symptom. ### Clinical course The patient had a 6-year history of clinically stable MS, albeit exhibiting radiographic progression despite strict adherence to daily

[1]  G. Cutter,et al.  Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing , 2019, Neurology.

[2]  M. Sormani,et al.  Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? , 2019, Neurotherapeutics.

[3]  R. Kinkel,et al.  Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis , 2019, Therapeutic advances in neurological disorders.

[4]  S. Richman,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies , 2017, The Lancet Neurology.

[5]  C. Louapre,et al.  Natalizumab-PML survivors with subsequent MS treatment , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[6]  Shin C. Beh,et al.  Extended interval dosing of natalizumab in multiple sclerosis , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  R. Gold,et al.  Rituximab postprogressive multifocal leukoencephalopathy: a Feasible therapeutic option in selected cases , 2014, Therapeutic advances in neurological disorders.

[8]  C. Louapre,et al.  Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? , 2014, Multiple sclerosis.

[9]  J. Sejvar,et al.  PML diagnostic criteria , 2013, Neurology.

[10]  R. Benedict,et al.  The thalamus and multiple sclerosis , 2013, Neurology.

[11]  M. Filippi,et al.  Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathy , 2012, Annals of neurology.

[12]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[13]  J. McArthur,et al.  PML-IRIS in patients with HIV infection , 2009, Neurology.